Literature DB >> 30190969

Systemic therapy for hepatocellular carcinoma: why do we keep failing?

Bo Hyun Kim1, Joong-Won Park1.   

Abstract

Entities:  

Keywords:  clinical trials; hepatocellular carcinoma; molecular targeted agent; sorafenib

Year:  2014        PMID： 30190969      PMCID： PMC6095331          DOI： 10.2217/hep.14.23

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  22 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

Review 2.  Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma.

Authors:  Terence C Chua; David L Morris
Journal:  Surg Oncol       Date:  2011-03-11       Impact factor: 3.279

3.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

4.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Authors:  Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S Kim; Magaly Zappa; Silvana Lanzalone; Xun Lin; Samuel Deprimo; Charles Harmon; Ana Ruiz-Garcia; Maria J Lechuga; Ann Lii Cheng
Journal:  Lancet Oncol       Date:  2009-07-06       Impact factor: 41.316

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

8.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

9.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316

10.  Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Young-Il Kim; Joong-Won Park; Hee-Won Kwak; Bo Hyun Kim; Ju Hee Lee; In Joon Lee; Tae Hyun Kim; Seong Hoon Kim; Young Hwan Koh; Hyun Beom Kim; Chang-Min Kim
Journal:  Liver Int       Date:  2014-04-10       Impact factor: 5.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.